Sunny Linnebur
Concepts (336)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Geriatric Nursing | 4 | 2020 | 23 | 2.060 |
Why?
| | Geriatrics | 6 | 2025 | 96 | 1.490 |
Why?
| | Students, Pharmacy | 5 | 2025 | 96 | 1.140 |
Why?
| | Health Services for the Aged | 6 | 2018 | 73 | 1.120 |
Why?
| | Polypharmacy | 7 | 2026 | 94 | 1.080 |
Why?
| | Practice Guidelines as Topic | 7 | 2020 | 1591 | 1.070 |
Why?
| | Curriculum | 5 | 2024 | 1079 | 0.910 |
Why?
| | Education, Pharmacy | 6 | 2025 | 125 | 0.890 |
Why?
| | Nursing Homes | 7 | 2022 | 171 | 0.830 |
Why?
| | Aged, 80 and over | 32 | 2025 | 8391 | 0.780 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2024 | 134 | 0.750 |
Why?
| | Anticoagulants | 3 | 2018 | 746 | 0.730 |
Why?
| | Prescription Drugs | 3 | 2012 | 110 | 0.720 |
Why?
| | Aged | 44 | 2026 | 26432 | 0.670 |
Why?
| | Pharmacists | 8 | 2021 | 260 | 0.670 |
Why?
| | Aspirin | 1 | 2024 | 405 | 0.650 |
Why?
| | Societies, Medical | 4 | 2025 | 907 | 0.620 |
Why?
| | Aging | 4 | 2020 | 1996 | 0.620 |
Why?
| | Vitamin D Deficiency | 4 | 2012 | 189 | 0.620 |
Why?
| | Bone Diseases | 1 | 2020 | 60 | 0.590 |
Why?
| | Muscular Diseases | 1 | 2020 | 110 | 0.590 |
Why?
| | Vitamin D | 5 | 2016 | 402 | 0.580 |
Why?
| | Hyponatremia | 2 | 2016 | 42 | 0.560 |
Why?
| | Medication Therapy Management | 3 | 2023 | 73 | 0.560 |
Why?
| | Vitamin K | 1 | 2018 | 46 | 0.530 |
Why?
| | Safety | 1 | 2019 | 347 | 0.510 |
Why?
| | Automobile Driving | 1 | 2019 | 157 | 0.500 |
Why?
| | Warfarin | 2 | 2009 | 179 | 0.500 |
Why?
| | Interprofessional Relations | 1 | 2019 | 275 | 0.490 |
Why?
| | Osteoporosis | 2 | 2010 | 240 | 0.490 |
Why?
| | Humans | 77 | 2026 | 146342 | 0.470 |
Why?
| | Internet | 2 | 2025 | 660 | 0.460 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2010 | 138 | 0.460 |
Why?
| | Attitude of Health Personnel | 2 | 2026 | 1219 | 0.460 |
Why?
| | Bupropion | 1 | 2016 | 47 | 0.460 |
Why?
| | Self Report | 2 | 2017 | 870 | 0.450 |
Why?
| | Educational Measurement | 5 | 2025 | 331 | 0.430 |
Why?
| | Hypercholesterolemia | 2 | 2025 | 95 | 0.410 |
Why?
| | Health Literacy | 1 | 2016 | 183 | 0.410 |
Why?
| | Antidepressive Agents | 1 | 2016 | 235 | 0.400 |
Why?
| | Health Status | 1 | 2019 | 827 | 0.400 |
Why?
| | Drug Therapy | 3 | 2017 | 85 | 0.400 |
Why?
| | Drug Monitoring | 2 | 2024 | 399 | 0.390 |
Why?
| | Vitamins | 3 | 2016 | 183 | 0.390 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2025 | 449 | 0.390 |
Why?
| | Pragmatic Clinical Trials as Topic | 3 | 2022 | 135 | 0.380 |
Why?
| | Health Personnel | 2 | 2019 | 754 | 0.380 |
Why?
| | Colorado | 10 | 2024 | 4595 | 0.380 |
Why?
| | Delivery of Health Care | 1 | 2020 | 947 | 0.370 |
Why?
| | Long-Term Care | 3 | 2022 | 118 | 0.370 |
Why?
| | Urinary Retention | 1 | 2012 | 23 | 0.360 |
Why?
| | Cholinergic Antagonists | 1 | 2012 | 24 | 0.360 |
Why?
| | Prostatic Hyperplasia | 1 | 2012 | 40 | 0.350 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2012 | 74 | 0.350 |
Why?
| | Cross Infection | 2 | 2011 | 258 | 0.350 |
Why?
| | Drug Approval | 1 | 2012 | 94 | 0.350 |
Why?
| | Male | 38 | 2026 | 73396 | 0.350 |
Why?
| | Health Communication | 1 | 2012 | 52 | 0.340 |
Why?
| | Antihypertensive Agents | 1 | 2015 | 519 | 0.340 |
Why?
| | Pharmacy Service, Hospital | 2 | 2019 | 90 | 0.340 |
Why?
| | Physicians | 2 | 2020 | 955 | 0.340 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2012 | 62 | 0.340 |
Why?
| | Proton Pump Inhibitors | 2 | 2024 | 101 | 0.330 |
Why?
| | Atherosclerosis | 2 | 2025 | 410 | 0.330 |
Why?
| | Schools, Pharmacy | 2 | 2024 | 48 | 0.330 |
Why?
| | Female | 39 | 2026 | 79499 | 0.320 |
Why?
| | Medication Adherence | 4 | 2024 | 535 | 0.320 |
Why?
| | Grifola | 1 | 2009 | 1 | 0.310 |
Why?
| | Herb-Drug Interactions | 1 | 2009 | 4 | 0.310 |
Why?
| | Central Nervous System Agents | 1 | 2009 | 7 | 0.300 |
Why?
| | International Normalized Ratio | 1 | 2009 | 55 | 0.300 |
Why?
| | United States | 12 | 2026 | 16136 | 0.300 |
Why?
| | Renal Insufficiency | 2 | 2016 | 173 | 0.290 |
Why?
| | Pain | 4 | 2018 | 790 | 0.290 |
Why?
| | Blood Pressure | 1 | 2015 | 1765 | 0.280 |
Why?
| | Central Nervous System Diseases | 1 | 2009 | 73 | 0.280 |
Why?
| | Patient Education as Topic | 3 | 2012 | 770 | 0.280 |
Why?
| | Fractures, Bone | 3 | 2016 | 436 | 0.280 |
Why?
| | Pneumonia | 2 | 2011 | 635 | 0.280 |
Why?
| | Accidental Falls | 3 | 2025 | 227 | 0.270 |
Why?
| | Depression | 3 | 2018 | 1575 | 0.270 |
Why?
| | Chronic Disease | 6 | 2026 | 1827 | 0.260 |
Why?
| | Drug Interactions | 4 | 2018 | 405 | 0.260 |
Why?
| | Dental Care for Chronically Ill | 1 | 2007 | 10 | 0.250 |
Why?
| | Faculty, Dental | 1 | 2007 | 8 | 0.250 |
Why?
| | Dementia | 2 | 2024 | 324 | 0.250 |
Why?
| | Bone and Bones | 1 | 2010 | 319 | 0.250 |
Why?
| | Hypertension | 1 | 2015 | 1272 | 0.250 |
Why?
| | Erectile Dysfunction | 1 | 2006 | 35 | 0.240 |
Why?
| | Education, Dental | 1 | 2007 | 38 | 0.240 |
Why?
| | Testis | 1 | 2007 | 158 | 0.240 |
Why?
| | Dietary Supplements | 1 | 2010 | 587 | 0.230 |
Why?
| | Primary Prevention | 2 | 2025 | 222 | 0.230 |
Why?
| | Community Pharmacy Services | 1 | 2005 | 46 | 0.220 |
Why?
| | Urinary Tract Infections | 2 | 2019 | 209 | 0.220 |
Why?
| | Cholinesterase Inhibitors | 1 | 2005 | 47 | 0.220 |
Why?
| | Patient Advocacy | 1 | 2005 | 73 | 0.220 |
Why?
| | Education, Distance | 1 | 2025 | 59 | 0.210 |
Why?
| | Diphosphonates | 1 | 2004 | 68 | 0.210 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2016 | 344 | 0.210 |
Why?
| | Nitrofurantoin | 1 | 2004 | 9 | 0.200 |
Why?
| | Fluconazole | 1 | 2004 | 24 | 0.200 |
Why?
| | Cognitive Dysfunction | 2 | 2021 | 481 | 0.200 |
Why?
| | Retrospective Studies | 14 | 2024 | 17438 | 0.200 |
Why?
| | Cholecalciferol | 2 | 2016 | 60 | 0.190 |
Why?
| | Research Design | 1 | 2009 | 1143 | 0.190 |
Why?
| | Middle Aged | 14 | 2024 | 36619 | 0.190 |
Why?
| | Antifungal Agents | 1 | 2004 | 153 | 0.190 |
Why?
| | Smoking Cessation | 1 | 2006 | 442 | 0.180 |
Why?
| | Secondary Prevention | 1 | 2024 | 248 | 0.180 |
Why?
| | Cyclohexanols | 1 | 2002 | 9 | 0.180 |
Why?
| | Vaginal Diseases | 1 | 2002 | 19 | 0.180 |
Why?
| | Professional Role | 4 | 2018 | 172 | 0.180 |
Why?
| | Research | 1 | 2005 | 421 | 0.180 |
Why?
| | Age Factors | 5 | 2015 | 3347 | 0.180 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2002 | 44 | 0.180 |
Why?
| | Nonprescription Drugs | 2 | 2016 | 68 | 0.180 |
Why?
| | Medicare | 2 | 2026 | 920 | 0.170 |
Why?
| | Caregivers | 2 | 2026 | 1080 | 0.170 |
Why?
| | United States Food and Drug Administration | 2 | 2012 | 208 | 0.170 |
Why?
| | Administration, Oral | 3 | 2018 | 872 | 0.170 |
Why?
| | Ergocalciferols | 2 | 2012 | 15 | 0.170 |
Why?
| | Prevalence | 4 | 2017 | 2861 | 0.160 |
Why?
| | Academic Medical Centers | 1 | 2024 | 561 | 0.160 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 1942 | 0.160 |
Why?
| | Artificial Intelligence | 1 | 2025 | 389 | 0.160 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 499 | 0.150 |
Why?
| | Self Care | 2 | 2014 | 396 | 0.150 |
Why?
| | Methenamine | 1 | 2019 | 4 | 0.150 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2019 | 16 | 0.150 |
Why?
| | Qualitative Research | 2 | 2026 | 1734 | 0.150 |
Why?
| | Smoking | 1 | 2006 | 1486 | 0.150 |
Why?
| | Education, Continuing | 1 | 2019 | 42 | 0.140 |
Why?
| | Surveys and Questionnaires | 5 | 2024 | 6073 | 0.140 |
Why?
| | Diet | 1 | 2007 | 1273 | 0.140 |
Why?
| | Health Promotion | 1 | 2026 | 786 | 0.140 |
Why?
| | Patients | 2 | 2011 | 183 | 0.140 |
Why?
| | Cross-Sectional Studies | 4 | 2024 | 5899 | 0.140 |
Why?
| | Risk Factors | 4 | 2025 | 10921 | 0.140 |
Why?
| | Sexism | 1 | 2019 | 70 | 0.140 |
Why?
| | Pharmacy | 1 | 2019 | 32 | 0.140 |
Why?
| | Recreation | 1 | 2018 | 27 | 0.140 |
Why?
| | Transitional Care | 1 | 2019 | 46 | 0.140 |
Why?
| | Alzheimer Disease | 1 | 2005 | 641 | 0.140 |
Why?
| | Physicians, Women | 1 | 2019 | 92 | 0.130 |
Why?
| | Drug Therapy, Combination | 2 | 2015 | 1036 | 0.130 |
Why?
| | Melatonin | 1 | 2019 | 165 | 0.130 |
Why?
| | Drug Prescriptions | 2 | 2010 | 314 | 0.130 |
Why?
| | Independent Living | 1 | 2018 | 114 | 0.130 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2017 | 13 | 0.130 |
Why?
| | Medication Reconciliation | 2 | 2019 | 31 | 0.130 |
Why?
| | Lung Diseases | 1 | 2004 | 787 | 0.120 |
Why?
| | Patient Transfer | 1 | 2020 | 224 | 0.120 |
Why?
| | Problem-Based Learning | 2 | 2017 | 99 | 0.120 |
Why?
| | Adult | 10 | 2026 | 41087 | 0.120 |
Why?
| | Health Education | 2 | 2016 | 346 | 0.120 |
Why?
| | Hemorrhage | 1 | 2002 | 825 | 0.120 |
Why?
| | Guideline Adherence | 2 | 2011 | 594 | 0.120 |
Why?
| | Refuse Disposal | 1 | 2016 | 4 | 0.120 |
Why?
| | Patient-Centered Care | 2 | 2023 | 553 | 0.120 |
Why?
| | Telemedicine | 1 | 2025 | 966 | 0.120 |
Why?
| | Ibuprofen | 1 | 2016 | 87 | 0.120 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 269 | 0.110 |
Why?
| | Cohort Studies | 3 | 2015 | 6077 | 0.110 |
Why?
| | Primary Health Care | 2 | 2024 | 1776 | 0.110 |
Why?
| | Emergency Service, Hospital | 2 | 2025 | 2363 | 0.110 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 43 | 0.110 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1327 | 0.110 |
Why?
| | Sleep Wake Disorders | 1 | 2019 | 314 | 0.110 |
Why?
| | Child Health | 1 | 2016 | 153 | 0.110 |
Why?
| | Leadership | 1 | 2019 | 414 | 0.110 |
Why?
| | Kansas | 2 | 2011 | 27 | 0.110 |
Why?
| | Sodium | 1 | 2016 | 196 | 0.110 |
Why?
| | Cardiovascular Diseases | 2 | 2024 | 2219 | 0.110 |
Why?
| | Missouri | 2 | 2011 | 66 | 0.110 |
Why?
| | Marijuana Use | 1 | 2018 | 218 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2016 | 172 | 0.100 |
Why?
| | Cognition Disorders | 1 | 2018 | 559 | 0.100 |
Why?
| | Faculty, Medical | 1 | 2017 | 309 | 0.100 |
Why?
| | Creatinine | 2 | 2007 | 511 | 0.100 |
Why?
| | Priapism | 1 | 2013 | 9 | 0.100 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2013 | 19 | 0.100 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2013 | 34 | 0.100 |
Why?
| | Hypoglycemic Agents | 2 | 2014 | 1412 | 0.100 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 18 | 0.100 |
Why?
| | Nursing Staff | 2 | 2010 | 41 | 0.100 |
Why?
| | Proline | 1 | 2013 | 79 | 0.100 |
Why?
| | Ambulatory Care | 3 | 2008 | 628 | 0.090 |
Why?
| | Blood Glucose | 2 | 2014 | 2360 | 0.090 |
Why?
| | Hoarding | 1 | 2012 | 1 | 0.090 |
Why?
| | Patient Care Team | 2 | 2011 | 701 | 0.090 |
Why?
| | Program Evaluation | 1 | 2017 | 952 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 2016 | 403 | 0.090 |
Why?
| | Assisted Living Facilities | 2 | 2016 | 20 | 0.090 |
Why?
| | Atrial Fibrillation | 1 | 2018 | 560 | 0.090 |
Why?
| | Education, Nursing, Continuing | 1 | 2011 | 46 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 2 | 2011 | 1408 | 0.080 |
Why?
| | Teaching | 1 | 2014 | 244 | 0.080 |
Why?
| | Kidney | 1 | 2019 | 1498 | 0.080 |
Why?
| | Electronic Health Records | 3 | 2014 | 1210 | 0.080 |
Why?
| | Administration, Inhalation | 1 | 2012 | 567 | 0.080 |
Why?
| | Stakeholder Participation | 2 | 2022 | 90 | 0.080 |
Why?
| | Interpersonal Relations | 1 | 2014 | 387 | 0.080 |
Why?
| | Prognosis | 1 | 2019 | 4351 | 0.080 |
Why?
| | Glucosamine | 1 | 2010 | 14 | 0.080 |
Why?
| | Chondroitin Sulfates | 1 | 2010 | 35 | 0.080 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 46 | 0.080 |
Why?
| | Piracetam | 1 | 2009 | 14 | 0.080 |
Why?
| | Parathyroid Hormone | 2 | 2008 | 118 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 790 | 0.070 |
Why?
| | Blood Chemical Analysis | 1 | 2010 | 109 | 0.070 |
Why?
| | Conflict of Interest | 1 | 2009 | 55 | 0.070 |
Why?
| | Hip Fractures | 1 | 2010 | 88 | 0.070 |
Why?
| | Infection Control | 1 | 2010 | 174 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2014 | 2623 | 0.070 |
Why?
| | Stroke | 1 | 2018 | 1287 | 0.070 |
Why?
| | Mass Screening | 3 | 2018 | 1307 | 0.070 |
Why?
| | Immunization Programs | 1 | 2010 | 194 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1763 | 0.070 |
Why?
| | Drug Dosage Calculations | 1 | 2008 | 27 | 0.070 |
Why?
| | Delphi Technique | 1 | 2009 | 350 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 731 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2010 | 354 | 0.060 |
Why?
| | Anticonvulsants | 1 | 2009 | 253 | 0.060 |
Why?
| | Nutrition Policy | 1 | 2007 | 56 | 0.060 |
Why?
| | Heptanoic Acids | 1 | 2007 | 67 | 0.060 |
Why?
| | Simvastatin | 1 | 2007 | 58 | 0.060 |
Why?
| | Phosphorus | 1 | 2007 | 89 | 0.060 |
Why?
| | Grounded Theory | 1 | 2026 | 47 | 0.060 |
Why?
| | Serum Albumin | 1 | 2007 | 147 | 0.060 |
Why?
| | Orthodontics, Corrective | 1 | 2006 | 8 | 0.060 |
Why?
| | Comorbidity | 1 | 2011 | 1665 | 0.060 |
Why?
| | Premedication | 1 | 2006 | 45 | 0.060 |
Why?
| | Interviews as Topic | 2 | 2026 | 930 | 0.060 |
Why?
| | Decision Making | 2 | 2011 | 993 | 0.060 |
Why?
| | Isoxazoles | 1 | 2006 | 57 | 0.060 |
Why?
| | Inpatients | 1 | 2010 | 540 | 0.060 |
Why?
| | Child | 3 | 2026 | 22693 | 0.060 |
Why?
| | Pyrroles | 1 | 2007 | 222 | 0.060 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 57 | 0.060 |
Why?
| | Life Expectancy | 1 | 2005 | 72 | 0.050 |
Why?
| | Metabolic Clearance Rate | 1 | 2004 | 115 | 0.050 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2005 | 80 | 0.050 |
Why?
| | Medical Records Systems, Computerized | 1 | 2005 | 95 | 0.050 |
Why?
| | Adolescent | 5 | 2026 | 22557 | 0.050 |
Why?
| | Onychomycosis | 1 | 2004 | 3 | 0.050 |
Why?
| | Tablets | 1 | 2024 | 41 | 0.050 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 60 | 0.050 |
Why?
| | Influenza, Human | 1 | 2010 | 640 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2016 | 1408 | 0.050 |
Why?
| | Hematologic Diseases | 1 | 2004 | 66 | 0.050 |
Why?
| | Heart Failure | 1 | 2017 | 2329 | 0.050 |
Why?
| | Communication | 3 | 2016 | 980 | 0.050 |
Why?
| | Outpatients | 1 | 2007 | 440 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2025 | 363 | 0.050 |
Why?
| | Time Factors | 2 | 2011 | 7109 | 0.050 |
Why?
| | Patient Discharge | 2 | 2020 | 997 | 0.050 |
Why?
| | Data Collection | 1 | 2005 | 650 | 0.050 |
Why?
| | Rheumatic Diseases | 1 | 2004 | 101 | 0.050 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2002 | 12 | 0.050 |
Why?
| | Pharmaceutical Services | 2 | 2016 | 76 | 0.040 |
Why?
| | Menstruation | 1 | 2002 | 44 | 0.040 |
Why?
| | Health Care Costs | 1 | 2005 | 423 | 0.040 |
Why?
| | Algorithms | 1 | 2010 | 1849 | 0.040 |
Why?
| | Sulfonamides | 1 | 2006 | 594 | 0.040 |
Why?
| | Quality of Life | 2 | 2023 | 3200 | 0.040 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2021 | 17 | 0.040 |
Why?
| | Palliative Care | 1 | 2010 | 1032 | 0.040 |
Why?
| | Calcium | 1 | 2007 | 1181 | 0.040 |
Why?
| | Liver Diseases | 1 | 2004 | 304 | 0.040 |
Why?
| | Nervous System Diseases | 1 | 2004 | 288 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2022 | 0.040 |
Why?
| | Hospitalization | 1 | 2010 | 2475 | 0.040 |
Why?
| | Child, Preschool | 2 | 2026 | 11913 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2019 | 156 | 0.040 |
Why?
| | Depressive Disorder | 1 | 2002 | 361 | 0.040 |
Why?
| | Healthcare Financing | 1 | 2018 | 6 | 0.040 |
Why?
| | Analgesics, Opioid | 1 | 2008 | 1221 | 0.040 |
Why?
| | Protons | 1 | 2019 | 96 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 1064 | 0.030 |
Why?
| | Biomarkers | 1 | 2010 | 4340 | 0.030 |
Why?
| | Guidelines as Topic | 2 | 2010 | 267 | 0.030 |
Why?
| | Anxiety | 2 | 2018 | 1125 | 0.030 |
Why?
| | Prospective Studies | 2 | 2007 | 8123 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2016 | 2070 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2018 | 244 | 0.030 |
Why?
| | Nephrology Nursing | 1 | 2016 | 16 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 282 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 745 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2016 | 152 | 0.030 |
Why?
| | Education, Medical, Undergraduate | 1 | 2017 | 208 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2019 | 515 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1888 | 0.030 |
Why?
| | Patient Readmission | 1 | 2020 | 778 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2018 | 1149 | 0.020 |
Why?
| | Obesity | 1 | 2007 | 3131 | 0.020 |
Why?
| | Cardiomyopathies | 1 | 2017 | 340 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2013 | 93 | 0.020 |
Why?
| | Medical Audit | 1 | 2013 | 78 | 0.020 |
Why?
| | Comprehension | 1 | 2014 | 175 | 0.020 |
Why?
| | Drug Evaluation | 1 | 2012 | 78 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1503 | 0.020 |
Why?
| | Neoplasms | 1 | 2008 | 2954 | 0.020 |
Why?
| | Sleep | 1 | 2019 | 896 | 0.020 |
Why?
| | Educational Status | 1 | 2014 | 466 | 0.020 |
Why?
| | Drug Therapy, Computer-Assisted | 1 | 2011 | 12 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2019 | 11821 | 0.020 |
Why?
| | Pharmacies | 1 | 2011 | 40 | 0.020 |
Why?
| | Electronic Mail | 1 | 2011 | 63 | 0.020 |
Why?
| | Personal Autonomy | 1 | 2011 | 61 | 0.020 |
Why?
| | Disclosure | 1 | 2011 | 91 | 0.020 |
Why?
| | Decision Trees | 1 | 2010 | 76 | 0.020 |
Why?
| | Midwestern United States | 1 | 2010 | 45 | 0.020 |
Why?
| | Medical Informatics | 1 | 2011 | 102 | 0.020 |
Why?
| | Complementary Therapies | 1 | 2011 | 93 | 0.020 |
Why?
| | Massage | 1 | 2010 | 42 | 0.020 |
Why?
| | Medication Errors | 1 | 2010 | 86 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2009 | 5439 | 0.020 |
Why?
| | Hypoglycemia | 1 | 2014 | 490 | 0.020 |
Why?
| | Epilepsies, Partial | 1 | 2009 | 62 | 0.020 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 266 | 0.020 |
Why?
| | Clinical Competence | 1 | 2016 | 1272 | 0.020 |
Why?
| | Self Administration | 1 | 2008 | 121 | 0.020 |
Why?
| | Young Adult | 2 | 2017 | 14330 | 0.020 |
Why?
| | Administration, Cutaneous | 1 | 2008 | 128 | 0.020 |
Why?
| | Oxycodone | 1 | 2008 | 53 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2008 | 192 | 0.020 |
Why?
| | Morphine | 1 | 2008 | 171 | 0.020 |
Why?
| | Fentanyl | 1 | 2008 | 126 | 0.010 |
Why?
| | Orthodontic Wires | 1 | 2006 | 6 | 0.010 |
Why?
| | Pain Management | 1 | 2010 | 421 | 0.010 |
Why?
| | Methadone | 1 | 2008 | 130 | 0.010 |
Why?
| | Kidney Diseases | 1 | 2009 | 428 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 426 | 0.010 |
Why?
| | Pain Measurement | 1 | 2006 | 573 | 0.010 |
Why?
| | Sex Factors | 1 | 2006 | 2107 | 0.010 |
Why?
|
|
Linnebur's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|